| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 72.56% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 09/22/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/09/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/02/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/24/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 04/03/2023 | 115.7% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 11/08/2022 | 55.31% | Goldman Sachs | $13 → $18 | Maintains | Neutral |
| 08/16/2022 | 12.17% | Goldman Sachs | $10 → $13 | Maintains | Neutral |
| 05/24/2022 | -13.72% | Goldman Sachs | $22 → $10 | Maintains | Neutral |
| 11/24/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/23/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/23/2021 | 150.22% | Goldman Sachs | → $29 | Initiates Coverage On | → Neutral |
What is the target price for Entrada Therapeutics (TRDA)?
The latest price target for Entrada Therapeutics (NASDAQ: TRDA) was reported by HC Wainwright & Co. on November 27, 2023. The analyst firm set a price target for $20.00 expecting TRDA to rise to within 12 months (a possible 72.56% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
The latest analyst rating for Entrada Therapeutics (NASDAQ: TRDA) was provided by HC Wainwright & Co., and Entrada Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a maintained with a price target of $25.00 to $20.00. The current price Entrada Therapeutics (TRDA) is trading at is $11.59, which is out of the analyst's predicted range.